Veraxa Biotech AG (VRXA)Healthcare | Biotechnology | Heidelberg, Germany | NasdaqGM
1.35 USD
-0.09
(-6.250%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.37 +0.02 (1.481%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:25 a.m. EDT
The immediate outlook is flat due to a severe disconnect between the current trading price and the established moving averages. While the stock recently staged a modest recovery from its yearly lows, it remains significantly depressed relative to its 50-day and 200-day averages, suggesting lingering selling pressure or a lack of institutional accumulation. This technical weakness is compounded by a very low reliability score in the short-term forecasting models, which renders any specific directional prediction for the coming weeks highly suspect. Looking further ahead, the investment case is neutral because the company lacks a multi-year price history to confirm a sustained trend, and the recent annual data shows no growth. Fundamentally, the business faces significant headwinds with negative earnings per share, negative return on equity, and negative operating cash flow, indicating that the company is currently burning cash rather than generating sustainable value. There is no dividend income to offset these risks, making the total return entirely dependent on future capital appreciation from a company that is still in a precarious financial position. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.095661 |
| AutoETS | 0.203333 |
| MSTL | 0.228981 |
| AutoTheta | 0.243684 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 20% |
| H-stat | 0.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 2.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 190,900,544 |
| Website | https://www.veraxa.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8619367 |
| Address1 | Im Neuenheimer Feld 584 |
| All Time High | 27.36 |
| All Time Low | 1.365 |
| Ask | 1.9 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 186,250 |
| Average Daily Volume3 Month | 479,901 |
| Average Volume | 479,901 |
| Average Volume10Days | 186,250 |
| Bid | 1.85 |
| Bid Size | 1 |
| Book Value | 2.7309957 |
| City | Heidelberg |
| Country | Germany |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.35 |
| Current Ratio | 2.202 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.43 |
| Day Low | 1.33 |
| Ebitda | -27,048,996 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -0.59 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.1931 |
| Fifty Day Average Change | -0.84309995 |
| Fifty Day Average Change Percent | -0.38443297 |
| Fifty Two Week Change Percent | -86.19367 |
| Fifty Two Week High | 27.36 |
| Fifty Two Week High Change | -26.01 |
| Fifty Two Week High Change Percent | -0.9506579 |
| Fifty Two Week Low | 1.33 |
| Fifty Two Week Low Change | 0.01999998 |
| Fifty Two Week Low Change Percent | 0.015037579 |
| Fifty Two Week Range | 1.33 - 27.36 |
| First Trade Date Milliseconds | 1,727,703,000,000 |
| Free Cashflow | 3,074,468 |
| Full Exchange Name | NasdaqGM |
| Fullday Change | -0.09 |
| Fullday Change Percent | -6.25 |
| Fullday Price | 1.37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.71152 |
| Held Percent Institutions | 0.020510001 |
| Implied Shares Outstanding | 141,407,813 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-06-11 |
| Language | en-US |
| Last Fiscal Year End | 1,735,603,200 |
| Long Business Summary | VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany. |
| Long Name | Veraxa Biotech AG |
| Market | us_market |
| Market Cap | 190,900,544 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_699307581 |
| Net Income To Common | -28,132,972 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 202,213,172 |
| Open | 1.43 |
| Operating Cashflow | -7,720,393 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 49 6221 3521330 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 1.48148 |
| Post Market Price | 1.37 |
| Post Market Time | 1,787,959,824 |
| Previous Close | 1.44 |
| Price Hint | 4 |
| Price To Book | 0.49432522 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.175 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.09 |
| Regular Market Change Percent | -6.25 |
| Regular Market Day High | 1.43 |
| Regular Market Day Low | 1.33 |
| Regular Market Day Range | 1.33 - 1.43 |
| Regular Market Open | 1.43 |
| Regular Market Previous Close | 1.44 |
| Regular Market Price | 1.35 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 313,514 |
| Return On Assets | -0.20456 |
| Return On Equity | -0.65287 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 141,407,813 |
| Shares Percent Shares Out | 0.0027 |
| Shares Short | 399,577 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 240,554 |
| Short Name | Veraxa Biotech AG |
| Short Ratio | 1.65 |
| Source Interval | 15 |
| Symbol | VRXA |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.054325 |
| Two Hundred Day Average Change | -7.704325 |
| Two Hundred Day Average Change Percent | -0.8509 |
| Type Disp | Equity |
| Volume | 313,514 |
| Website | https://www.veraxa.com |
| Zip | 69,120 |